NTRK1 and neoplasm: While the analysis of ALK, ROS1, and RET rearrangements is generally limited to several tumor types, NTRK1, NTRK2, and NTRK3 are currently positioned as “agnostic” targets, calling, in theory, for systematic testing of the wide spectrum of tumors [6].